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Visual Abstract
Huntington’s disease (HD) patients suffer from a progressive neurode-
generation that results in cognitive, psychiatric, cardiovascular, and motor
dysfunction. Disturbances in sleep/wake cycles are common among HD
patients with reports of delayed sleep onset, frequent bedtime awaken-
ings, and fatigue during the day. The heterozygous Q175 mouse model of
HD has been shown to phenocopy many HD core symptoms including
circadian dysfunctions. Because circadian dysfunction manifests early in
the disease in both patients and mouse models, we sought to determine
if early intervention that improve circadian rhythmicity can benefit HD and
delay disease progression. We determined the effects of time-restricted
feeding (TRF) on the Q175 mouse model. At six months of age, the
animals were divided into two groups: ad libitum (ad lib) and TRF. The
TRF-treated Q175 mice were exposed to a 6-h feeding/18-h fasting
regimen that was designed to be aligned with the middle of the time when
mice are normally active. After three months of treatment (when mice
reached the early disease stage), the TRF-treated Q175 mice showed
improvements in their locomotor activity rhythm and sleep awakening
time. Furthermore, we found improved heart rate variability (HRV), sug-
gesting that their autonomic nervous system dysfunction was improved.
Importantly, treated Q175 mice exhibited improved motor performance
compared to untreated Q175 controls, and the motor improvements
were correlated with improved circadian output. Finally, we found that the
expression of several HD-relevant markers was restored to WT
levels in the striatum of the treated mice using NanoString gene
expression assays.
Significance Statement
Huntington’s disease (HD) is a genetically caused disease with no known cure. Lifestyle changes that not
only improve the quality of life but also delay disease progression for HD patients are greatly needed. In this
study, we found that time-restricted feeding (TRF) improves activity/rest rhythms in the Q175 mouse model
of HD. This treatment also improved motor performance and heart rate variability (HRV) in the HD mice.
Finally, TRF altered the expression of HD relevant markers in the striatum. Our study demonstrates the
therapeutic potential of circadian-based treatment strategies in a preclinical model of HD.
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Introduction
Huntington’s disease (HD) is caused by an expanded
CAG repeat within the first exon of the Huntingtin (Htt)
gene. The mutated HTT protein leads to dysfunction of a
large range of cellular processes, including cytoskeletal
organization, metabolism, and transcriptional activities
(Bourne et al., 2006; Grimbergen et al., 2008; Fisher et al.,
2014). As result, HD patients suffer from progressive
neurodegeneration that inflicts cognitive, psychiatric, car-
diovascular, and motor dysfunction. The genetic compo-
nents greatly determine the age of symptom onset and
the severity. Generally, the longer the CAG repeat, the
earlier the age of onset and the greater the severity of the
symptoms (Langbehn et al., 2010). Still, even among pa-
tients with the same CAG repeat length, large variabilities
in the onset of symptoms (around a decade) and their
severity have been reported (Gusella et al., 2014). In
addition, studies have shown that environmental factors
also affect the disease progression (Wexler et al., 2004).
Those reports raise the possibility of environmental mod-
ifiers to the disease and suggest that lifestyle changes can
increase the health span of the patients. This possibility is
important to pursue as there are no known cures for HD.
Disturbances in the timing of sleep, typified by frequent
bedtime awakenings, prolonged latency to fall asleep, and
more naps during the awake phase, are extremely com-
mon in HD and often become apparent years before the
onset of classic motor symptoms (Cuturic et al., 2009;
Aziz et al., 2010a; Goodman et al., 2011). Similarly, mouse
models of HD also exhibit a disrupted circadian rest/
activity cycle that mimics the symptoms observed in hu-
man patients (Morton et al., 2005; Kudo et al., 2011; Loh
et al., 2013). This body of work supports the hypothesis
that circadian dysfunctions may interact with HD pathol-
ogy and exacerbate the symptoms. To test this hypothe-
sis, we have been using the Q175 knock-in model of HD.
In previous work (Loh et al., 2013), we have characterized
the impact of age (3, 6, 9, and 12 months) and gene
dosage (Het and Hom) on the degradation of circadian
rhythms in locomotor activity and other HD core symp-
toms. Recently, a detailed RNA-seq analysis of striatum,
cortex, and liver of the Q175 line has been published
(Langfelder et al., 2016); therefore, we have a good un-
derstanding of the transcriptional changes that occur with
age in this model. Finally, recent work has carefully char-
acterized age-related changes in the electroencephalo-
gram (EEG) in both Hom and Het Q175 (Fisher et al.,
2016). This wealth of data makes the Het Q175 an ideal
preclinical model to examine the impact of circadian in-
terventions on disease trajectory.
The central circadian clock responsible for the genera-
tion of daily rhythms is localized in the suprachiasmatic
nucleus (SCN) in the hypothalamus. While lighting condi-
tions are a critical environmental input to this timing sys-
tem, a body of recent work has lead us to appreciate that
the feed/fast cycle is also a powerful regulators of the
circadian system (Hamaguchi et al., 2015). While progres-
sive, age-related SCN dysfunction has been reported in
HD mouse models (Bartlett et al., 2016), a time-restricted
feeding (TRF) regimen promises therapeutic potential and
can benefit even SCN-lesioned mice (Hara et al., 2001;
Mulder et al., 2014). For example, mice under TRF con-
sume equivalent calories from a high-fat diet as those with
ad libitum (ad lib) access yet are protected against obe-
sity, hyperinsulinemia, and inflammation and have im-
proved motor coordination (Hatori et al., 2012). In the
present study, we examined the impact of imposing a 6-h
feeding/18-h fasting regimen that was aligned to the mid-
dle [zeitgeber time (ZT) 15-21] of the period when mice
normally active (ZT 12-24). The treatment was applied to
Q175 Hets starting when the mutants were six months of
age and ending when they were nine months. We selected
this age range because the Het Q175 start to show dis-
rupted sleep/wake cycles and motor symptoms are just
beginning.
Materials and Methods
The work presented in this study followed all guidelines
and regulations of the UCLA Division of Animal Medicine
that are consistent with the Animal Welfare Policy State-
ments and the recommendations of the Panel on Eutha-
nasia of the American Veterinary Medical Association.
Animals
The Q175 mice used in this study were males on the
C57BL6/J background. They arose from a spontaneous
expansion of the CAG repeat in the CAG140 transgenic
knock-in line (Menalled et al., 2012). The mice were
heterozygous (Het) for the Q175 allele with an average of
189  3 CAG repeats. Mutant mice were obtained from
The Jackson Laboratory from a colony managed by the
CHDI Foundation. The animals were singly housed within
light-tight chambers with independently controlled light-
ing conditions: 12 h of light followed by 12 h of dark (12/12
h LD). The chambers were in the same animal housing
facility with controlled temperature and humidity, and
each chamber held eight cages of mice, grouped together
by feeding treatment. All animals received cotton nestlets,
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and water was made available at all times. To confirm the
effect of timed feeding on daily rhythms and motor per-
formance, we also examined WT mice at nine months of
age.
TRF
Mice were first entrained to a 12/12 h LD cycle for a
minimum of two weeks before any treatment. Experimen-
tal animals were randomly assigned to one of two feeding
conditions: food available ad lib and food available for 6 h
during the middle of the active phase during ZT 15-21. By
definition, ZT 12 referrers to when the lights go off when
the mice are in an LD cycle. Experimental mice were
singly housed in cages with a custom made programma-
ble food hopper that could temporally control access to
food (Diet Teklad 7013: fat, 18 kcal%; caloric density, 3.13
kcal/g) and prevent food consumption during restricted
times. These cages were also equipped with an infrared
(IR) motion detector to give us the ability to measure cage
activity. The mice were held in these conditions for a total
of three months (from six to nine months of age).
Monitoring of cage locomotor activity
Experimental mice were singly housed in cages with the
food hopper as well as IR motion sensors. The locomotor
activity recorded as previously described (Wang et al.,
2017). Mice were entrained to a 12/12 h LD cycle for a
minimum of two weeks before data collection. Locomotor
activity data were recorded using Mini Mitter data loggers
in 3-min bins, and 10 d of data were averaged for analysis.
We used the 10 d of activity data collected just before the
motor performance tests during the final two weeks of
the TRF schedule. The data were analyzed to determine
the period and rhythmic strength as previously described
(Loh et al., 2013; Wang et al., 2017). The periodogram
analysis uses a 2 test with a threshold of 0.001 signifi-
cance, from which the amplitude of the periodicities is
determined at the circadian harmonic to obtain the rhythm
power. The amount of cage activity over a 24-h period
was averaged over 10 d and reported here as the arbitrary
units (a.u.)/h. The number of activity bouts and the aver-
age length of bouts were determined using Clocklab (Ac-
timetrics), where each bout was counted when activity
bouts were separated by a gap of 21 min (maximum gap:
21 min; threshold: 3 counts/min). The onset variability was
determined using Clocklab by drawing the best-fit line
over the 10 d, and averaging the differences between
activity onset and best-fit regression of each day.
Monitoring of immobility-defined sleep behavior
Immobility-defined sleep was determined as described
previously (Loh et al., 2013; Wang et al., 2017). Mice were
housed in see-through plastic cages containing bedding
(without the addition of nesting material) and the food
hopper. A side-on view of each cage was obtained, with
minimal occlusion by the food bin or water bottle, both of
which were top-mounted. Cages were side-lit using IR-
LED lights. Video capture was accomplished using sur-
veillance cameras with visible light filters (Gadspot Inc)
connected to a video-capture card (Adlink Technology
Inc) on a Dell Optiplex computer system. ANY-maze soft-
ware (Stoelting Co) was used to track the animals.
Immobility was detected when 95% of the area of the
animal stayed immobile for 40 s, as was previously deter-
mined to have 99% correlation with simultaneous EEG/
EMG-defined sleep (Pack et al., 2007; Fisher et al., 2012).
Continuous tracking of the mice was performed for a
minimum of five sleep-wake cycles, with randomized vis-
its (one to two times per day) by the experimenter to
confirm mouse health and video recording. The 3rd and
4th sleep-wake cycles were averaged for further analysis.
Immobility-defined sleep data were exported in 1 min
bins, and total sleep time was determined by summing the
immobility durations in the rest phase (ZT 0-12) or active
phase (ZT 12-24). An average wave form of hourly
immobile-sleep over the two sleep-wake cycles was pro-
duced during the final week of TRF. Variability of awake
time was determined using Clocklab to draw the best-fit
line over the sleep cycles, and the differences between
sleep offset and best-fit regression of each sleep cycle
were averaged.
Rotarod test. Accelerating version
The rotarod apparatus (Ugo Basile) is commonly used
to measure motor coordination and balance. This appa-
ratus is, in essence, a small circular treadmill. It consists
of an axle or rod thick enough for a mouse to rest over the
top of it when it is not in motion and a flat platform a short
distance below the rod. The rod is covered with smooth
rubber to provide traction while preventing the mice from
clinging to the rod. In this study, mice were placed on top
of the rubber covered rod. When the mice moved at the
pace set by the rotation rate of the rod, they would stay on
top of it. When mice no longer move at the selected pace
they dropped a short distance to the platform below. The
time a mouse remained on the rod, before dropping to the
platform was called the latency to fall. Following a 15-min
habituation to the testing room, mice were placed on the
slowly rotating rod. The rod gradually accelerated from 5
rpm to 38 rpm over the course of the trial. The length of
time the mouse stays on the rod was recorded. A two-day
protocol for the accelerating rotarod tests was used. On
the first day, the mice were trained on the rotarod over five
trials. The maximum length of each trial was 600 s, and
mice were allowed to rest for a minimum of 60 s between
trials. On the second day, mice were tested on the rotarod
and the latency to fall from the rotarod was recorded from
five trials. Mice were again allowed to rest for a minimum
of 60 s between trials. Data from each mouse were ana-
lyzed after averaging the times from all five trials. The
apparatus was cleaned with 70% alcohol and allowed to
dry completely between trials. A dim red-light (2 lux) was
used for illumination during active phase testing (night).
Challenging beam test
The challenging beam test is a modified version of the
beam traversal test first described by Goldberg and col-
leagues (Goldberg et al., 2003), and was used to charac-
terize the motor deficits of Q175 mutant mice in previous
studies (Loh et al., 2013, Wang et al., 2017). The beam
narrows in four intervals from 33 mm  24 mm  18 mm 
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6 mm, with each segment spanning 253 mm in length.
Apparatus and methods used are similar to those de-
scribed by Fleming and colleagues (Fleming et al., 2013).
The home cage of each mouse is put on the end of the
beam as the motivating factor. In this study, animals were
trained on the beam for five consecutive trials on two
consecutive days. During each trial, each mouse was
placed on the widest end of the beam and allowed to
cross with minimal handling by the experimenter. On the
testing day, a metal grid (10  10-mm spacing, formed
using 19-gauge wire) was overlaid on the beam. This
overlaid grid increased the difficulty of the beam traversal
task and provided a visual reference for foot slips made
while crossing the grid. Each mouse was subjected to five
consecutive trials, which were recorded by a camcorder
under dim red-light conditions (2 lux), supplemented with
IR lighting for video recording. The videos were scored
post hoc by two independent observers for the number of
missteps (errors) made by each mouse. The observers
were masked as to the treatment group of the mice that
they were scoring. An error was scored when any foot
dipped below the grid. The number of errors was aver-
aged across the five trials per mouse to give the final
reported values. The apparatus was cleaned with 70%
alcohol and allowed to dry completely between trials. A
dim red-light (2 lux) was used for illumination during active
phase testing (night).
Automatic outputs. Core body temperature (CBT),
heart rate (HR), and HR variability (HRV)
For the telemetry measurements, methods employed
were similar to those previously described (Schroeder et al.,
2016; Cutler et al., 2017). Two groups (ad lib and TRF) of
Het Q175 mice (n  7/group) were surgically implanted
with a wireless radio-frequency transmitter (ETA-F20,
Data Sciences International). Mice were singly housed in
cages with the food hopper. Cages were placed atop
telemetry receivers (Data Sciences International) in a light
and temperature-controlled chamber. Standard rodent
chow was provided for both groups. Data collection be-
gan two weeks after surgery. HR was extrapolated from
ECG waveforms using the RR interval.
Data collection and analysis were performed as de-
scribed previously (Cutler et al., 2017). Data were ex-
tracted in 20-s intervals then filtered to remove extreme
noise. Remaining valid data segments were averaged into
1-h bins across the 24-h cycle. Mean normal to normal
intervals (NN, in ms) and SD of all NN intervals (SDNN, in
ms) were calculated for the time domain analysis.
NanoString analysis of gene expression
Tissue collection and data analysis were performed as
described previously (Wang et al., 2017). Four weeks after
the final behavioral tests were performed, the Q175 mu-
tants were anesthetized with isoflurane before dissection
of the striatum at ZT 15. The brain tissue samples were
flash frozen and stored at 80°C before NanoString anal-
ysis. The NanoString analysis was performed by LabCorp
using a custom CodeSet designed to interrogate 100 tran-
scripts previously implicated in transcriptional changes in
the striatum of Q175 mice (Langfelder et al., 2016). The
signal intensity of individual genes was normalized by ad-
justing to internal positive standards within each sample.
Eight housekeeping genes were included in the CodeSet:
Gins1, Myh15, Pank2, Poc1b, Pum2, Slc25a15, Ssrp1, and
Utp3. The expression levels for each probe within a sample
were scaled using the geometric mean of the eight house-
keeping genes for each sample. Each mouse was an indi-
vidual sample as tissue did not need to be pooled. The fold
change of signal intensity was derived by comparing the
normalized means between the ad lib group and the TRF
group.
Pathway analysis
To study the HD-changed gene expression data in the
context of biological networks, the gene expression data
of TRF-treated Q175 and untreated Q175 control samples
were analyzed with the Ingenuity Pathway Analysis (IPA)
system (Ingenuity Systems). Datasets containing gene iden-
tifiers and corresponding expression values were uploaded
in the application. Each gene identifier was mapped to its
corresponding gene object in Ingenuity Pathways Knowl-
edge. A cutoff of corrected p value (i.e., q value  0.005)
was set to identify genes whose expression was signifi-
cantly different as a result of the treatment. These genes
were overlaid onto a global molecular network developed
from information contained in the Ingenuity Pathways
Knowledge Base. Functional analysis using the IPA pro-
gram identified the biological functions that were most
significant to the dataset (uncorrected Fisher’s exact test
p  0.05).
Statistical analysis
We were interested in determining if TRF can delay the
progression of symptoms in the Q175 mouse model;
Therefore, treated Q175 mice (TRF group) were compared
to age-matched untreated Q175 mice (ad lib group) in all
experiments. The sample size per group was determined
by both our empirical experience with the variability in the
prior measures in the Q175 mice (Loh et al., 2013) and a
power analysis (SigmaPlot, SYSTAT Software) that as-
sumed a power of 0.8 and an  of 0.05. For the behavioral
measures, the analysis was done by two observes masked
as to the experimental condition and their values averaged.
To assess the impact of TRF after three months, we applied
a t test for the analysis. To determine the impact of the
treatment on temporal activity, sleep, CBT, HR, and HRV
waveforms, we used a two-way repeated measures
ANOVA (two-way RM ANOVA) with treatment and time as
factors. To determine the impact of the treatment on
errors made in each beam of the challenging beam test,
we used a two-way ANOVA with treatment and beam # as
factors. F values are reported as F (degrees of freedom
between groups, degrees of freedom within groups). Pair-
wise multiple comparison procedures were made using
the Holm–Sidak method. Correlations between circadian
parameters and motor performance were examined by
applying Pearson correlation analysis. Statistical analysis
was performed using SigmaPlot. The dataset was exam-
ined for normality (Shapiro–Wilk test) and equal variance
(Brown–Forsythe test). The power of the statistical tests is
reported in Table 1. Between-group differences were de-
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termined significant if p  0.05. All values are reported as
group mean  SEM.
Results
By using the programmable food hopper, we could
temporally control access to food (ZT 15-21) and prevent
food consumption for the rest of the daily cycle. During
this 6-h interval, the mice would eat as much as they
wanted and the amount of food consumed daily did not
vary between the Het Q175 groups (ad lib: 2.8  0.4 g;
TRF: 2.8  0.2 g, t(14)  0.13, p  0.900, t test
a). At the
time when we performed the recordings and motor as-
says, the body weights were not different in Q175 mice
under TRF compared to age-matched controls (ad lib:
23.9  0.4 g; TRF: 24.5  0.4 g, t(14)  1.03, p  0.320,
t testb).
TRF increased the amplitude of diurnal rhythms in
Het Q175 line
At early disease stage (nine months of age), the TRF-
treated group showed greatly improved circadian loco-
motor activity rhythms (Fig. 1A–D), evidenced by the
stronger rhythmic power (ad lib: 32.1  2.2; TRF: 43.4 
2.9, t(14)  3.12, p  0.008, t test
c) and lower activity
onset variability (ad lib: 27.3  4.6 min; TRF: 15.8  2.4
min, t(14)  2.2, p  0.045, t test
d) than the control group.
The amount of cage activity was also increased under the
TRF regimen (ad lib: 75.3  5.9 a.u./h; TRF: 160.7  21.1
a.u./h, t(14)  42, p  0.005, t test
e). These increases in
rhythm power and activity amount coincided with a de-
creased total number of activity bouts (ad lib: 10. 8  0.9;
TRF: 7.9  0.6, t(14)  2.6, p  0.021, t test
f). A temporal
activity wave form indicated more robust activity levels in
the TRF-treated group at night when the mice should be
active (Fig. 1E). A two-way RM ANOVAg revealed a sig-
nificant effect of time (F(23,382)  70.07, p  0.001), treat-
ment (F(1,14)  10.82, p  0.005), and a significant
interaction between the two factors (F 8.24, P 0.001).
A further examination of activity bouts at night (ZT 12-24)
revealed that the TRF group had longer bout lengths (ad
lib: 60.6  17.5 min; TRF: 128.8  27.8 min, t(14)  48,
p  0.038, t testh) without a significant increase in the
number (ad lib: 7.6  0.6; TRF: 5.4  0.9, t(14)  2.15, p 
0.05, t testi), suggesting that the robust amplitude of
diurnal rhythms in the TRF group was due to the consol-
Table 1. List of distribution, statistical test, and power for each dataset analyzed in this study
Letter Data structure Type of test Power
a food consumption Normal distribution t test 0.052
b body weight Normal distribution t test 0.050
c power Normal distribution t test 0.956
d onset Normal distribution t test 0.536
e cage activity Normal distribution t test 0.843
f bout # Normal distribution t test 0.605
g waveform Normal distribution Two-way ANOVA Time 1.000
Treatment 0.843
h bout duration Normal distribution t test 0.729
i bout # Normal distribution t test 0.413
j sleep waveform Normal distribution Two-way ANOVA Time 1.000
Treatment 0.179
K sleep duration Normal distribution t test 0.050
l bout # Normal distribution t test 0.328
m bout duration Normal distribution t test 0.895
n wake time onset Normal distribution t test 0.944
o cycle to cycle Normal distribution t test 0.440
p daytime activity Normal distribution t test 0.884
q activity waveform Normal distribution Two-way ANOVA Time 1.000
Treatment 0.997
r average CBT Normal distribution t test 0.529
s CBT waveform Normal distribution Two-way ANOVA Time 1.000
Treatment 0.729
t HR average Normal distribution t test 0.382
u HR amplitude Normal distribution t test 0.560
v HR waveform Normal distribution Two-way ANOVA Time 1.000
Treatment 0.895
w average HVR Normal distribution t test 0.632
x HRV waveform Normal distribution Two-way ANOVA Time 1.000
Treatment 1.000
y rotarod Normal distribution t test 0.911
z beam errors Normal distribution t test 0.989
aa error by beam Normal distribution Two-way ANOVA beam 1.000
Treatment 1.000
The first column lists the superscript lowercase letter referring to statistical test in the Results section. The second column is the structure of the data (normal
distribution or non-normal). Each of the datasets was examined for normality (Shapiro–Wilk test) and equal variance (Brown–Forsythe test). The third column
lists the statistical test. The fourth column gives the observed power value of the statistical test calculated from the actual data.
New Research 5 of 16
January/February 2018, 5(1) e0431-17.2017 eNeuro.org
idated and high amount of locomotor activity during the
active phase (Fig. 1F,G). Under TRF, the activity parame-
ters in the Q175 mice were no longer significantly different
from WT (Tables 1, 2). These findings demonstrate that
TRF treatment significantly improved the activity rhythms
of the HD mutant mice.
Figure 1. Locomotor activity rhythms were improved by the TRF regimen. A, Examples of cage activity rhythms recorded from Q175
mutants under control (left) and TRF (right) conditions. The activity levels in the actograms were normalized to the same scale (85%
of the maximum of the most active individual). Each row represents two consecutive days, and the second day is repeated at the
beginning of the next row. The orange bar on the top of actograms indicates the time when food hopper is opened. B, The strength
of the activity rhythm is indicated by the power (%V) of the 2 periodogram analysis. C, The averaged level of cage activity. D, The
averaged variation in onset from the best-fit regression line. E, Average waveforms from 10 d of cage activity (1-h window) are shown
and SEs across animals are indicated. F, The number of activity bouts (separated by a gap of 21 mins or more) during rest phase (ZT
0-12), active phase (ZT 12-24), and 24 h are reported as the level of fragmentation of the circadian activity cycle. Black bars represent
Q175 mutants under ad lib condition, and orange bars represent Q175 mutants under timed feeding condition. G, The average length
of activity bouts during their active phase. The white/black bar on the top of actograms (A) and waveforms (E) indicates the 12/12 h
LD cycle. The temporal activity wave form was analyzed using a two-way RM ANOVA with time and treatment as factors. Other
comparisons between Q175 cohorts were made using a t test. Asterisks represent significant differences due to TRF regimen
compared to ad lib controls (p  0.05); n  8/group.
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TRF shifted the timing but not the total amount of
sleep behavior in the Het Q175 mice
The immobility-defined sleep behavior was measured
using video recording in combination with automated
mouse tracking analysis software. During the 6 h when
food was available at night, the TRF-treated Q175 mice
slept less than untreated Q175 controls (Fig. 2A). A two-
way RM ANOVAj was used to analyze the temporal pat-
tern of sleep (1-h bins) of each group. The analysis
revealed significant effect of time (F(23,382)  36.575, p 
0.001) and significant interaction between time and treat-
ment (F(23)  2.23, p  0.002), but the effect of treatment
did not reach a significant level (F(1,14) 2.033, p 0.155).
No significant changes were detected in the total amount
of sleep time over a 24-h cycle (ad lib: 722.5  25.6 min;
TRF: 686.3 28.4 min, t 0.95, p 0.36, t testk; Fig. 2B).
No significant difference was found in the total number of
sleep bouts over a 24-h cycle (ad lib: 8.2  0.4; TRF: 9.3 
0.8, t(14)  58, p  0.33, t test
l). The sleep bouts at night
were significantly shorter in the TRF group than the con-
trol group (ad lib: 160.4 31.6; TRF: 65.5 7.9, t(14) 93,
p 0.007, t testm), suggesting that TRF group had shorter
naps than the control group in their active phase (Fig.
2C,D).
The TRF treatment advanced the phase when the Q175
mice transitioned from sleep to awake states (ad lib: ZT
12.6 0.2 h; TRF: ZT 11.9 0.1 h, t(14) 3.84, p 0.002,
t testn; Fig. 2E). The TRF group also exhibited a more
precise awakening time than the Q175 control mutants
(ad lib: 37.7  6.3 min; TRF: 19.3  5.4 min, t(14)  2.21,
p  0.044, t testo; Fig. 2F). Under TRF, the beginning of
activity and the cycle-to-cycle variability in sleep behavior
in the Q175 mice were no longer significantly different
from WT (Tables 2, 3). Overall, these findings demonstrate
that the TRF regimen improved sleep behavior in Q175
mice.
TRF improved autonomic outputs in the Het Q175
mice
It has been shown that dysfunction in the circadian
regulation of autonomic outputs can be detected early in
disease progression in the Q175 mice (Cutler et al., 2017).
In the present study, we measured the impact of TRF on
activity, CBT, HR, and HRV measured simultaneously in
freely moving Q175 mice (Fig. 3). The TRF Q175 mice
exhibited higher levels in activity, CBT, and HR at some
phases of the daily cycle (Fig. 3A–C). TRF also reduced
the inappropriate activity during the daytime (ZT 0-12)
when mice are normally less active (ad lib: 618.6  96.6
a.u.; TRF: 308.4  33.9 a.u., t(12)  3.03, p  0.010, t
testp). A two-way RM ANOVAq was applied on the activity
wave form and significant effects of time (F(23,334) 21.86,
p  0.001), treatment (F(1,12)  23.81, p  0.001) and
interaction (F(23)  3.68, p  0.001) were detected. In
addition, the daily 24-h averaged CBT was not signifi-
cantly different between the two groups (ad lib: 37.1 
0.1°C.; TRF: 36.7  0.3°C, t(12)  3.03, p  0.17, t test
r).
The TRF-treated group showed a lower CBT at the dark/
light transition (ZT 23-2; Fig. 3B). A two-way RM ANOVAs
confirmed significant effects of time (F(23,334) 28.64, p
0.001) and treatment (F(1,12)  7.65, p  0.006) without an
interaction between the two factors (F(23)  1.05, p 
0.398). Despite no difference in the daily 24-h averaged
HR (ad lib: 405. 9 8.0 bpm; TRF: 424.1 10.2, t1.4,
p  0.190, t testt), the amplitude of the rhythm (max/min
ratio) was improved by the TRF regimen (ad lib: 1.5 0.02
bpm; TRF: 1.6  0.03 bpm, t  2.18, p  0.049, t testu;
Fig. 3E). The TRF group exhibited higher HR (ZT 13-17)
when the food was available. As measured by two-way
ANOVAv, significant effects of time (F(23,334)  10.21, p 
0.001) and treatment (F(1,12)  11.39, p  0.001) were
detected. But no interaction between the two factors (F(23) 
1.52, p  0.06) was detected. Finally, the TRF-treated
group exhibited higher levels in HRV in the rest phase as
well as the beginning of active phase than the Q175
control group (Fig. 3D). The TRF-treated Q175 mice had
significantly higher 24-h averaged HRV than the control
Q175 mice (ad lib: 13.7  0.8 msec.; TRF: 17.0  1.0
msec, t(12)  2.5, p  0.028, t test
w). A two-way RM
ANOVAx confirmed significant effect of time (F(23,334) 
8.23, p  0.001) and treatment (F(1,12)  39.6, p  0.001)
without a significant interaction (F(23)  1.33, p  0.140).
Table 2. Comparisons of age-matched WT under ad lib conditions to Q175 mice under ad lib or TRF regimen (n  8/group)
WT ad lib WT ad lib vs Q175 ad lib WT ad lib vs Q175 TRF
Locomotor activity rhythm AVG  SEM Difference p value Difference p value
Rhythmic power (V%) 32.59  2.12 3.93 0.234 10.82 0.009
Cage activity (a.u/h) 152.47  19.08 75.67 0.002U 8.23 0.7
Onset variability (min) 23.20  2.84 4.13 0.461 7.41 0.068
Bouts/d 8.44  0.39 2.34 0.007 0.50 0.517
Average bout length (rest-phase) 166.82  22.33 106.20 0.002 38.01 0.305
Sleep behavior rhythm
Daily sleep 665.42  16.28 57.12 0.081 20.89 0.534
Bouts/d 8.44  0.79 0.25 0.779 0.88 0.443
Average bout length (night) 85.54  21.52 74.83 0.075 20.03 0.721
Awake time (ZT) 12.03  0.1 0.60 0.002U 0.10 0.329
Awake deviation time I (min) 13.62  3.26 24.07 0.004 5.70 0.382
Motor performance
Latency to fall (s) 320.65  24.37 64.65 0.119 99.4 0.028
Crossing errors (#) 3.09  0.21 4.35 <0.001 1.88 0.002U
The results of t tests are reported if data passed normality tests. DF  14. For parameters that did not pass normality tests, the Mann–Whitney rank-sum test
was run and the U statistic reported; p  0.05 was considered significant. In this and subsequent tables significant differences are shown in bold.
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Overall, the TRF regimen improved the daily rhythms in
physiologic, autonomically-driven outputs.
TRF improved motor performance in the Het Q175
mice
One of the defining symptoms of HD is the incidence of
movement disorders in early-stage patients and we hy-
pothesized that TRF may improve the motor symptoms.
To test this hypothesis, we assessed motor performance
using two tests that have been shown to detect motor
coordination deficits in Q175 mice: the accelerating ro-
tarod (Fig. 4A) and challenging beam tests (Fig. 4B). The
Q175 mice on TRF had a longer latency to fall compared
to age-matched Q175 ad lib-fed mutants (ad lib: 256 
30.4 min; TRF: 420.1  32.2 min, t(14)  3.7, p  0.002,
t testy). In addition, the treated Q175 mice made signifi-
cantly fewer errors compared to control Q175 mice (ad lib:
7.4  0.5; TRF: 4.9  0.5, t(14)  3.23, p  0.006, t test
z).
Breaking down the errors made by beam width, the two-
way ANOVAaa revealed a significant effect of treatment
(F(1,14)  15.22, p  0.001), effect of beam width (F(3,62) 
26.17, p  0.001), and interaction between the two fac-
tors (F(3)  3.924, p  0.013). Post hoc analysis indicates
that the main difference between treated and control
Q175 mice were the errors in the narrowest beam (ad lib:
3.4  0.5; TRF: 1.8  0.2, t  4.84, p  0.001, t test).
The TRF-treated Q175 mice which showed the most
improved circadian output also had better performance in
the two motor tests (Fig. 4C). In a XYZ grid composed of
key activity rhythms parameters and performance of mo-
Figure 2. TRF prevented disease-caused awakening time without altering the amount of sleep behavior. Video recording in
combination with automated mouse tracking analysis software was used to measure immobility-defined sleep. A, Running averages
(1-h window) of immobility-defined sleep in Q175 mutants with ad lib (black) and timed feeding (orange) are plotted. The white/black
bar on the top of wave form indicates the 12/12 h LD cycle. B–F, Quantification of the immobility-defined sleep rhythms. The temporal
sleep wave form was analyzed using a two-way RM ANOVA with time and treatment as factors. Other comparisons between Q175
cohorts were made using a t test. Asterisks represent significant differences due to TRF regimen compared to ad lib controls (p 
0.05); n  8/group.
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tor tests, there were two distinctive clusters which indi-
cated that the mice with improved locomotor activity
rhythm performed better in both motor tests. The corre-
lation analysis indicated that the rhythmic power tended
to be positively correlated with the amount of time staying
on the accelerating rotarod (coefficient  0.54, p  0.17)
and was negatively correlated with numbers of errors made
crossing the narrowest beam (coefficient0.52, p 0.04)
in the TRF group. This correlation was not detected in the
Q175 control group (coefficient  0.16 and 0.13, respec-
tively). Similarly, the TRF-treated group showed a negative
correlation between their cage activity level and beam cross-
ing errors (coefficient  0.51, p  0.01). This correlation
was, again, not detected in the Q175 control group (coeffi-
cient  0.06). These data indicate that the TRF-driven
improvement in activity rhythms is correlated with the reduc-
tion in beam crossing errors.
Expression of multiple HD markers in striatum were
altered by TRF
Striatum is one of the key brain structures of the
cortical-basal ganglia circuit controlling motor function,
and it has been shown to be particularly vulnerable in HD.
Previous work has identified HD-driven changes in tran-
scription in the striatum of the Q175 mouse (Langfelder
et al., 2016). Using NanoString technology, we examined
the impact of TRF on changes in gene expression of HD
markers in the striatum of the Q175 mice as previously
described (Wang et al., 2017). The expression patterns
were compared to Q175 ad lib controls (Table 4). The TRF
regimen altered expression of immediate early genes
such as Arc, Erg1,2,4, and Fos, as well as receptors for
neurotransmitters such as acetylcholine, histamine, 5HT,
tachykinin, and dynorphin (Fig. 5A). The IPA analysis tool
was applied to the total dataset (Table 5) to identify corre-
sponding enriched pathways and biofunctions (Table 6). The
top canonical pathways identified included (in descending
order of significance): G protein-coupled receptor (GPCR)
signaling, cAMP-mediated signaling, and glutamate recep-
tor signaling. The top upstream regulators included BDNF,
CREB1, and HTT. Hence, the TRF treatment significantly
altered the patterns of expression of genes linked to HD and
modulated multiple transcriptional pathways.
Discussion
A range of circadian deficits in the mouse models of HD
have been reported, detailing the impact on rhythms in
behavior and physiology (Bourne et al., 2006; Ciammola
et al., 2006; Grimbergen et al., 2008; Cuturic et al., 2009;
Kuljis et al., 2012; Fisher et al., 2016). The findings suggest
that the most common sleep-related clinical complaints of
HD patients (i.e., difficulty falling asleep, frequent awaken-
ings during sleep, and difficulty staying awake during the
active cycle) are due, at least in part, to the disease-induced
dysfunction in the circadian system. These findings raise the
possibility of treating HD symptoms by improving the regu-
larity/robustness of circadian rhythms in activity and rest
(Wang et al., 2017; Whittaker et al., 2017).
In the present study, the Het Q175 mice were allowed
access to their food (standard chow, 6 h) nightly for three
months starting at an age before the onset of motor
symptoms. We confirmed that the animals consumed
similar amounts of food and the body weights were not
significantly decreased by this feeding regimen. We dem-
onstrate that the nightly TRF regimen improved the daily
activity rhythm with increases in the rhythmic strength as
measured by power of the periodogram and decreases in
cycle-to-cycle variability in activity onset. Prior work in WT
mice did not find an impact of TRF on locomotor activity
patterns (Hatori et al., 2012). While we are not sure of the
difference, we did evaluate older mice (six months) who
may be already exhibiting some age-related decline in
locomotor activity rhythms. The TRF treatment also ad-
vanced the time that the mice ended their sleep phase
without changes in total amount of sleep per cycle. Crit-
ically, the TRF regimen also improved performance of the
HD mutant mice on two different motor tests.
The beneficial impact of TRF on motor performance
could be dependent on or independent from the improve-
ments in circadian output. We examined this issue by
Table 3. Comparisons of age-matched WT under ad lib to regimen (n  8/group)
WT TRF WT TRF vs WT ad lib
Locomotor activity rhythm AVG  SEM Difference p value
Rhythmic power (V%) 57.03  3.15 24.44 <0.001
Cage activity (a.u/h) 269.96  20.24 117.49 <0.001
Onset variability (min) 31.54  2.49 8.34 0.028U
Bouts/d 6.8  0.38 1.64 0.009
Average bout length (rest-phase) 202.55  25.87 35.74 0.313
Sleep behavior rhythm
Daily sleep 646.25  31.61 19.17 0.598
Bouts/d 9.5  0.61 1.06 0.279
Average bout length (night) 60.06  12.8 25.47 0.326
Awake time (ZT) 11.90  0.16 0.12 0.095
Awake deviation time I (min) 19.57  6.04 5.94 0.42
Motor performance
Latency to fall (sec) 457.08  22.12 136.43 <0.001
Crossing errors (#) 3.28  0.31 0.19 0.6
Body weight (g) 29.02  0.87 0.76 0.343
Find the values of ad lib in Table 2. The results of t tests are reported if data passed normality tests. DF  14. For parameters that did not pass normality
tests, the Mann–Whitney rank-sum test was run and the U statistic reported; p  0.05 was considered significant.
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taking advantage of the animal-to-animal variation in the
impact of the treatment on circadian and motor function.
Using our most sensitive motor assay (i.e., challenge
beam test), we found that the improved circadian behav-
ior was correlated with improved motor function in the
TRF group (coefficient  0.52, P  0.04). This finding
leads us to conclude that improved circadian timing un-
derlies the improved motor function in the treated mice.
Furthermore, a variety of different approaches aiming to
boost circadian output have now been found to improve
motor functions in different HD mouse models. There is
evidence that improving the sleep/wake cycle with sleep-
inducing drugs (Pallier et al., 2007; Kantor et al., 2016),
stimulants (Cuesta et al., 2012; Whittaker et al., 2017),
bright light and restricted wheel access (Cuesta et al.,
2014), and blue light (Wang et al., 2017) can treat HD
symptoms. This body of work supports our general hy-
pothesis that TRF improves circadian robustness and
acts via this mechanism to delay disease symptoms in
HD.
Our data clearly demonstrate that the benefits of TRF
extend to physiologic measures such as HRV. Cardiovas-
cular events are a major cause of early death in the HD
population (Lanska et al., 1988; Sørensen and Fenger
1992) and the dysfunctional autonomic nervous system
may be linked to the increased cardiovascular suscepti-
bility. HRV measures the variation in the beat-to-beat
(R-R) interval. It reflects the dynamic balance of sympa-
thetic and parasympathetic control of heart function, and
displays a robust circadian rhythm. A prior study demon-
Figure 3. Autonomic output rhythms were improved by the TRF regimen. The autonomic outputs from ad lib (black circles) and TRF
(orange triangles) Q175 mice were recorded simultaneously using telemetry device. A–D, Hourly running averages of activity (A), CBT
(B), HR (C), and HRV from both groups are plotted (D). E, The HR rhythm amplitude, determined by the ratio of max and min of the
day, in control and TRF-treated Q175 mice. F, The 24-h averaged HRV in control and TRF-treated Q175 mice. The temporal
waveforms of autonomic outputs were analyzed using a two-way RM ANOVA with time and treatment as factors. Other comparisons
between Q175 cohorts were made using a t test. Asterisks represent significant differences due to TRF regimen compared to ad lib
controls (p  0.05); n  7/group.
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strated that the Q175 mice exhibit a loss of circadian
control in HRV day/night differences, as well as an overall
decrease in HRV over a 24-h period when compared to
WT controls (Cutler et al., 2017). It is worthwhile to note
that a similar decrease in HRV has also been reported in
HD patients beginning during the presymptomatic stage
of disease progression (Andrich et al., 2002; Aziz et al.,
2010b). Reduced HRV is generally considered an indica-
Figure 4. TRF improved motor performance in the Q175 HD model. A, The accelerating rotarod test revealed that the TRF treatment
improved motor performance by showing longer latency to fall. B, The challenging beam motor test indicated that the TRF treatment
improved performance (fewer errors) by making fewer errors when the mice crossed the balanced beam. C, The circadian parameters
and the performance in the two motor tests of individual mouse in ad lib group (black circles) and TRF group (orange triangles) are
plotted in a 3D-XYZ grid. In this XYZ grid, there are two distinctive clusters, suggesting that the mouse with stronger circadian rhythms
performed better in both motor tests. Comparisons between Q175 cohorts were made using a t test. Asterisks represent significant
differences due to TRF regimen compared to ad lib controls (p  0.05). The correlations between circadian parameters and motor
performance are described in the text; n  8/group.
Table 4. Top 5 HD markers in the striatum of Q175 altered by the TRF treatment
Comparison Q175 vs WT Ad lib vs TRF
Age 2 months 6 months o 10 months 9 months
Gene Symbol Full name Log2 fold change Log2 fold change p value
Striatum
Fos FBJ osteosarcoma oncogene ns 2 ns 1 0.0004
Htr2a 5-Hydroxytryptamine (serotonin) receptor 2A ns ns ns 1 0.0005
Hrh3 Histamine receptor H3 ns 2 2 1 0.0009
Chrm4 Cholinergic receptor, muscarinic 4 2 2 2 1 0.0012
Tacr1 Tachykinin receptor 1 ns 2 2 1 0.0020
P value of the t test comparison with Q175 housed under ad lib is shown. Asterisk indicates HD markers changed in both the striatum and cortex. Tran-
scripts increased by the treatment (Log2 fold change) are shown in green (1) and those decreased by the treatment in red (2). Transcripts without
significant change (p  0.05) are shown in gray (ns); 24% gene expressions in the striatum and 7% gene expressions in the cortex are altered by the TRF
treatment. Among altered genes in striatum, 50% genes (13/24) that are shown downregulated in Q175 controls (comparison with age-matched WT con-
trols (Lengfelder et al., 2016) are upregulated by TRF.
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tion of poor cardiovascular health and a predictor for
cardiovascular disease and mortality (Thayer et al., 2010).
To our knowledge, this is the first study showing that a
TRF regimen can improve HRV in a disease model.
Prior work in Drosophila has also demonstrated the
benefits of TRF in ameliorating age-related cardiovascular
decline (Melkani and Panda, 2017). In this model, TRF
downregulates expression of gene involved in mitochon-
drial electron transport while increasing expression of a
cytoplasmic chaperonin (Gill et al., 2015). This study also
found that mutations in circadian clock genes prevented
the benefits of TRF. TRF improved the amplitude of the
day/night rhythms in many circadian-regulated tran-
scripts. In mice, genetic disruption of the circadian clock
results in a variety of cardiovascular deficits (Paschos and
FitzGerald, 2010; Young, 2016). Together, this work sug-
gests that TRF can work in concert with the photic regu-
lation of the circadian system to boast the amplitude and
perhaps the phasing of the molecular clock-work.
Lifestyle interventions have been suggested to be pre-
ventative and therapeutic for diseases associated with
aging, such as type-2 diabetes, cardiovascular disease
and increasingly neurodegenerative disorders. For exam-
ple, caloric restriction (CR) has consistently been found to
prolong life span and protect against a variety of patho-
logic conditions (Heilbronn and Ravussin 2003; Fontana
Figure 5. Altered expression level of multiple HD markers in the striatum of the Q175 HD model. A, Differentially expressed genes in
the striatum observed between TRF group and ad lib group using NanoString (find all gene expression data in Table 6). The same
Q175 mice that underwent activity/sleep monitoring and behavioral tests were allowed to recover for four weeks from manipulations
before tissue collection. The signal intensity of individual genes was normalized by adjusting to internal positive standards within each
sample (see Materials and Methods). B, Enriched functional clustering in the striatum using the IPA analysis tool (based on data in
Table 6; uncorrected Fisher’s exact test p value  0.05). The clusters of interest with statistical significance are picked and enriched
biofunctions in those picked clusters are shown (in descending order of significance). The picked clusters include Behavior (p 
2.72E-17, color orange), Cell-to-cell signaling and interaction (p  1.02E-17, color blue), inflammatory response (p  2.87E-04, color
pink), and neurologic disease (p  8.74E-14, color green).
Table 5. Top 10 canonical pathways and upregulators iden-
tified using IPA analysis in striatum of Q175 under TRF
regimen
Ingenuity canonical pathways log (p value)
G protein-coupled receptor signaling 7.65
cAMP-mediated signaling 6.73
Glutamate receptor signaling 6.08
Neuropathic pain signaling in dorsal horn
neurons
5.02
Gi signaling 4.94
Synaptic long-term potentiation 3.38
Gq signaling 3.03
iNOS signaling 2.88
CREB signaling in neurons 2.87
Serotonin receptor signaling 2.77
Upstream regulator log (p value)
BDNF 13.41
CREB1 12.27
Cocaine 11.87
CNTF 11.14
HTT 10.82
TET1 10.40
GDNF 9.74
ADCYAP1R1 9.72
Dalfampridine 8.95
Haloperidol 8.90
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et al., 2004). Conceptually, the TRF regimen used in the
present study is quite distinct from CR. While CR focuses
on overall, dramatic reduction in energy intake, TRF em-
phasizes the temporal pattern of fasting without a reduc-
tion in overall energy intake. Mechanistically, TRF may
activate the same beneficial biochemical pathways as CR
(Mattson et al., 2014; Longo and Panda 2016) but would
likely be easier to implement in a patient population
(Scheen, 2008; Marder et al., 2009). In humans, the time
of food availability would be during the day when food is
normally consumed while the fast would be extended past
the normal night. Prior studies have demonstrated the
benefits of an 8:16 feed/fast cycle in improving the met-
abolic state and motor coordination of mice without alter-
ing caloric intake or nutrient composition (Hatori et al.,
2012; Chaix et al., 2014). In the HD-N171-82Q mouse
model, CR improves motor performance and survival
while reducing cell death (Duan et al., 2003). Prior work in
the R6/2 HD model has shown that TRF can restore
HD-driven disruption in circadian gene expression in the
liver (Maywood et al., 2010) and improve locomotor ac-
tivity as well as exploratory behavior in the open field
without increasing life span (Skillings et al., 2014). To-
gether, these data suggest that feeding schedules could
play a role in the treatment of HD and could lead to the
development of new treatment options for neurodegen-
erative disorders.
The mechanisms underlying the beneficial effects of the
TRF regimen on Q175 mouse model are uncertain and
likely mediated by multiple pathways. Our data indicate
that the TRF treatment changes the transcriptional envi-
Table 6. Full dataset of expression of HD markers in the
striatum of Q175 that are tested by using NanoString tech-
nology. Bold text indicates significant difference between ad
lib and TRF feeding protocols
Gene symbol Log (p value) Log 2 Fold Change
Aco2 0.51 0.09
Aif1 0.58 0.13
Apba2bp 0.60 0.37
Arc 2.58 0.11
Bdnf 0.54 0.56
Bhlhb2 0.16 0.12
C1qc 0.17 0.14
C3 0.49 0.05
C4a 0.60 0.08
calb1 0.39 0.11
Calm1 0.74 0.03
Calm2 1.43 0.16
Calm3 0.06 0.09
Cdkn1c 0.04 0.21
Chat 0.55 0.07
Chga 0.54 0.01
Chrm1 0.33 0.13
Chrm4 2.92 0.17
Chrna4 1.43 0.15
Chrnb2 0.62 0.07
Cnr1 1.02 0.04
Cth 0.28 0.09
Dnajb5 0.13 0.04
Drd1a 1.06 0.21
Drd2 1.00 0.25
Egr1 1.84 0.13
Egr2 2.34 0.24
Egr3 0.86 0.08
Egr4 1.54 0.21
F8a 1.24 0.01
Fos 3.39 0.23
Fth1 0.34 0.03
Gabra1 0.43 0.02
Gabrd 0.05 0.11
Gclc 1.74 0.15
Gclm 0.07 0.08
Gfap 1.03 0.03
Grm2 1.59 0.47
Grm5 1.33 0.01
Hace1 2.03 0.03
Hmox1 0.86 0.20
Hrh3 3.04 0.31
Htr1a 0.03 0.36
Htr1b 1.22 0.27
Htr2a 3.32 0.15
Htt 0.50 0.10
Il12b 0.73 0.04
Il6 0.41 0.16
Kcnip2 1.05 0.10
Lonp1 0.67 0.05
Nfe2l2 0.01 0.05
Ngf 0.75 0.26
Nos1 0.96 0.02
Nos3 0.09 0.10
Npy 2.35 0.02
Nqo1 0.90 0.03
Ntrk1 1.18 0.13
Ntrk2 1.12 0.09
Pde10a 0.97 0.20
Pde9a 1.59 0.02
(Continued)
Table 6. Continued
Gene symbol Log (p value) Log 2 Fold Change
pdyn 1.89 0.22
Penk 1.82 0.26
Penk1 1.80 0.23
Per2 2.50 0.01
Ppargc1a 0.08 0.05
Ppp1r1b 1.61 0.19
Ptpn5 0.76 0.09
Pvalb 1.42 0.02
Rgs4 0.09 0.00
Rrs1 0.88 0.16
Ryr1 0.15 0.14
Sap25 0.72 0.03
Slc17a6 1.81 0.15
Slc17a7 0.10 0.70
Slc1a2 0.12 0.09
Slc6a3 0.78 0.16
Slco6b1 0.61 0.41
Snap25 0.12 0.08
Sod1 1.01 0.01
Sod2 0.00 0.05
Sst 1.96 0.17
Tac1 1.09 0.15
Tacr1 2.71 0.33
Tfeb 0.98 0.03
Tmsb10 0.05 0.24
Vgf 0.69 0.08
hHTT polypro 0.01 0.12
mHTT polypro 0.15 0.01
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ronment in a brain region intimately involved in HD, i.e.,
the striatum. We used the NanoString technology with the
IPA platform to analyze the transcriptional changes evoked
by TRF. We found that50% of genes (13/24) that had been
shown downregulated in Q175 controls in a prior study
(comparison with age-matched WT controls (Langfelder
et al., 2016) were upregulated by this treatment (Table 4),
suggesting our circadian manipulation may exert benefi-
cial effects through these pathways (Table 5). For exam-
ple, striatal histamine receptor H3 (Hrh3) may connect
improved circadian rhythms to improved motor functions.
Hrh3, a GPCR, is strongly expressed in the cortico-striatal
circuits controlling motor behavior (Pollard et al., 1993).
Prior work found a significant reduction in Hrh3 radioli-
gand binding in tissue of HD patients (Goodchild et al.,
1999) suggesting a central role of the histaminergic sys-
tem in this basal ganglia disorder. Histamine is a well-
known regulator of the sleep-wake cycle (Lin et al., 2011;
Gondard et al., 2013) and specifically, H3R modulates
striatal neurons through its regulation of glutamate (El-
lender et al., 2011), GABA (Garcia et al., 1997; Ellender
et al., 2011), and dopamine (Schlicker et al., 1993;
González-Sepúlveda et al., 2013) release. In a recent
study, we found that daily treatment with an H3R inverse
agonist improved several behavioral measures in the
Q175 mice including activity and sleep rhythms, explor-
atory behavior, mood (Whittaker et al., 2017). GPCR sig-
naling and glutamate receptor signaling are the top three
pathways identified in the IPA analysis as being regulated
by TRF. Unfortunately, the feeding schedule did not re-
duce the levels of mutant Htt (Table 6). Nevertheless,
identifying treatments that improve the standard of living
for HD patients remains an important goal. Future work
will need to specifically evaluate the role of the histamin-
ergic system in mediating the benefits of TRF for the
sleep-wake cycles as well as motor performance.
Conclusion
Imposed feeding cycles have the capacity to synchro-
nize or increase the amplitude of circadian oscillations
throughout the body. Disturbances in the sleep/wake cy-
cle are by now a well-established symptom of neurode-
generative diseases, and here we show that we can treat
the HD symptoms by controlling the timing of food avail-
ability. The results presented in our preclinical study sug-
gest that a TRF regimen could be a useful management
tool for neurodegenerative disease patients. More gener-
ally, the present study adds to a growing body of evi-
dence that improvements in “circadian hygiene” through
attention to regularity in environmental signaling, in-
cluding timed feeding, leads to improvements in health
outcomes for a wide range of human diseases including
neurodegenerative disorders.
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